Circulating tumor cell counts (CTC) as prognostic of overall survival (OS) in SWOG S0421-docetaxel with or without atrasentan for metastatic castration resistant prostate cancer (mCRPC).
Year: 2012
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Nicholas J. Vogelzang, Benjamin Ely, Louis M. Fink, Amir Goldkorn, Catherine M. Tangen, Przemyslaw Twardowski, Peter J. Van Veldhuizen, Neeraj Agarwal, Michael Anthony Carducci, J. P. Monk, Ram H Datar, Mark Garzotto, Philip C. Mack, Primo Lara, Celestia S. Higano, Maha Hussain, David I. Quinn, Richard J Cote, Ian Murchie Thompson
Institutions: Comprehensive Cancer Centers of Nevada, USC Norris Comprehensive Cancer Center, City Of Hope National Medical Center, City of Hope, The University of Kansas Cancer Center, University of Utah, Huntsman Cancer Institute, Johns Hopkins University, The Ohio State University, University of Miami, Portland VA Medical Center, University of California, Davis, Seattle Cancer Care Alliance, University of Washington, U-M Rogel Cancer Center, The University of Texas at San Antonio Health Science Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2996935049